컴파운딩 약국 시장 예측(-2031년) : 제품별, 유형별, 치료 용도별, 무균성별, 최종사용자별, 경쟁별, 지역별

The global compounding pharmacy market is projected to reach USD 21.01 billion by 2031 from USD 15.48 billion in 2026, reflecting a CAGR of 6.3% over the forecast period. The global compounding pharmacy market is projected to expand significantly over the forecast period, driven by rising demand for personalized medications, customized dosage forms, and formulations not commercially available.

Market growth is supported by the increasing prevalence of chronic and complex conditions, greater adoption of patient-specific therapies, and growing reliance on compounded medications during drug shortages. Advances in automated compounding systems, digital prescription management, and precision dosing technologies are further improving efficiency and quality. However, stringent regulatory requirements, high investments in sterile compounding facilities, specialized workforce requirements, and quality-control challenges may constrain market expansion, particularly for smaller compounding pharmacies.

By product type, oral drugs held the largest share of the compounding pharmacy market in 2025.

By product type, the compounding pharmacy market is segmented into topical drugs, oral drugs, parenteral drugs, rectal drugs, nasal drugs, ophthalmic drugs, and other products. Among these, the oral drugs segment holds a significant position in the compounding pharmacy market, supported by rising demand for personalized medications. Compounded capsules, tablets, lozenges, solutions, and suspensions enable customized dosages, flavors, excipients, and release profiles for pediatric, geriatric, and chronic disease patients. The growing prevalence of endocrine disorders, diabetes, and other chronic conditions further drives demand. Technological advancements in taste masking, sustained-release formulations, and bioavailability enhancement improve patient adherence and treatment outcomes. Increasing emphasis on personalized medicine, compliance with FDA and USP standards, and expanding availability through hospitals, specialty clinics, and retail pharmacies continue to support segment growth.

By therapeutic application, the pain management segment reported the largest market share in 2025.

By therapeutic application, the market is segmented into pain management, hormone replacement therapy, dermal disorders, nutritional supplements, and other therapeutic applications. In 2025, the pain management segment held the largest share of the compounding pharmacy market, driven by the widespread prevalence of acute and chronic pain. Growing cases of arthritis, neuropathic pain, cancer-related pain, migraines, and postoperative conditions are increasing demand for customized analgesic formulations. Compounding pharmacies enable personalized strengths, dosage forms, and delivery methods, supporting improved tolerability and adherence. Advances in topical preparations, transdermal systems, sustained-release formulations, and localized therapies further expand treatment options. Rising demand for individualized pain management, an aging population, and increasing healthcare awareness are expected to support continued segment growth.

Asia Pacific is growing at the highest CAGR in the compounding pharmacy market from 2026 to 2031.

The compounding pharmacy market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. During the forecast period, Asia Pacific is expected to register the highest CAGR, driven by rising demand for personalized medications, increasing healthcare expenditure, and expanding pharmaceutical and biotechnology industries. Regional growth is further supported by improving healthcare infrastructure, growing awareness of customized therapies, increasing prevalence of chronic diseases, and rising adoption of advanced compounding technologies. Expanding hospital networks, specialty clinics, and compounding pharmacies, along with investments in sterile compounding facilities and quality-control systems, are strengthening the region's capabilities. Additionally, pharmaceutical and healthcare expansion in China, Japan, South Korea, and India is expected to drive demand for customized drug formulations and compounding services.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side (70%) and Demand Side (30%)
• By Designation: Managers (45%), CXOs & Directors (30%), and Executives (25%)
• By Region: North America (40%), Europe (25%), Asia Pacific (20%), Latin America (10%), and the Middle East & Africa (5%)

Companies Profiled in the Report:

• Baxter (US)
• Empower Pharmacy (US)
• B. Braun (Germany)
• Fagron (Netherlands)
• QuVa Pharma (US)
• SCA Pharma (US)
• Nephron Pharmaceuticals (US)
• Leiters Health (US)
• Pharmaxo (UK)
• Icon Group (Australia)
• Roseway Labs (UK)
• ITH Pharma (UK)
• Pencol Compounding Pharmacy (Canada)
• Formula 8 (South Africa)
• Aurora Compounding Pharmacy (Canada)

Research Coverage:

This research report categorizes the compounding pharmacy market by product, compounding type, therapeutic application, sterility, and end user. The report includes detailed information on the main factors affecting growth in the compounding pharmacy market, such as drivers, restraints, challenges, and opportunities. It also features an in-depth analysis of key industry players, offering insights into their business overview, products, solutions, strategies, collaborations, partnerships, and agreements. The report covers recent developments such as new approvals, launches, collaborations, acquisitions, and other updates in the compounding pharmacy market.

Key Benefits of Buying the Report:

The report will help market leaders and new entrants by providing the closest estimates of revenue for the entire compounding pharmacy market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop appropriate go-to-market strategies. This report enables stakeholders to understand the market's key indicators and provides information on the main market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

• Analysis of key drivers (persistent drug shortages in North America and Europe, full enforcement of USP standards, safety push for ready-to-administer and standardized doses, continued demand creating supply gap for GLP-1 drugs, and trend toward personalization of doses), restraints (resolution of GLP-1 shortages reduces reliance on compounded alternatives, stricter FDA oversight and insanitary conditions enforcement, and limitations on bulk drug substances), opportunities (expansion of hospital outsourcing into anesthesia, critical care, ophthalmic & chemo-adjuncts and radiopharmaceutical compounding standardization), and challenges (capacity bottlenecks in API, excipient supply, and CCI/testing, and limited quality-system maturity and gaps in stability/BUD evidence generation) influencing the growth of the market.
• Service Development/Innovation: Detailed insights on upcoming technologies, research & development activities in the compounding pharmacy market.
• Market Development: Comprehensive information about lucrative markets; the report analyzes the market across varied regions.
• Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the compounding pharmacy market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the compounding pharmacy market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

• 2.1 KEY INSIGHTS & MARKET HIGHLIGHTS
• 2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH
• 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
• 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

• 3.1 COMPOUNDING PHARMACY MARKET OVERVIEW
• 3.2 COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE & REGION
• 3.3 COMPOUNDING PHARMACY MARKET: GEOGRAPHIC SNAPSHOT
• 3.4 COMPOUNDING PHARMACY MARKET SHARE, BY STERILITY, 2026 VS. 2031

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 Persistent drug shortages in North America and Europe
    • 4.2.1.2 Enforcement of USP standards
    • 4.2.1.3 Push for ready-to-administer (RTA) and standardized doses
    • 4.2.1.4 Continued demand-supply gap for GLP-1 drugs
    • 4.2.1.5 Trend towards personalization of doses
  • 4.2.2 RESTRAINTS
    • 4.2.2.1 Resolution of GLP-1 shortages and reduced reliance on compounded alternatives
    • 4.2.2.2 Stricter FDA oversight and intensified enforcement of unsanitary conditions violations
    • 4.2.2.3 Limitations on bulk drug substances
  • 4.2.3 OPPORTUNITIES
    • 4.2.3.1 Expansion of hospital outsourcing into anesthesia, critical care, ophthalmic, and chemo-adjuncts
    • 4.2.3.2 Radiopharmaceutical compounding standardization
  • 4.2.4 CHALLENGES
    • 4.2.4.1 Capacity bottlenecks in API, excipient supply, and critical compounding infrastructure testing
    • 4.2.4.2 Limited quality-system maturity and gaps in stability/BUD evidence generation
• 4.3 UNMET NEEDS & WHITE SPACES
• 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
• 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

• 5.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.1.1 THREAT OF NEW ENTRANTS
  • 5.1.2 THREAT OF SUBSTITUTES
  • 5.1.3 BARGAINING POWER OF SUPPLIERS
  • 5.1.4 BARGAINING POWER OF BUYERS
  • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.2 MACROECONOMIC OUTLOOK
  • 5.2.1 INTRODUCTION
  • 5.2.2 GDP TRENDS & FORECAST
  • 5.2.3 TRENDS IN GLOBAL COMPOUNDING PHARMACY MARKET
• 5.3 VALUE CHAIN ANALYSIS
• 5.4 ECOSYSTEM ANALYSIS
  • 5.4.1 ROLE IN ECOSYSTEM
• 5.5 PRICING ANALYSIS
  • 5.5.1 INDICATIVE PRICING ANALYSIS FOR COMPOUNDING PHARMACY PRODUCTS, BY KEY PLAYER, 2025
  • 5.5.2 INDICATIVE PRICING ANALYSIS FOR COMPOUNDING PHARMACY PRODUCTS, BY REGION, 2025
• 5.6 KEY CONFERENCES & EVENTS, 2026-2027
• 5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.8 INVESTMENT & FUNDING SCENARIO
• 5.9 IMPACT OF 2025 US TARIFFS ON COMPOUNDING PHARMACY MARKET
  • 5.9.1 INTRODUCTION
  • 5.9.2 KEY TARIFF RATES
  • 5.9.3 PRICE IMPACT ANALYSIS
  • 5.9.4 IMPACT ON COUNTRY/REGION
    • 5.9.4.1 US
    • 5.9.4.2 Europe
    • 5.9.4.3 Asia Pacific
    • 5.9.4.4 Rest of the World
  • 5.9.5 IMPACT ON END-USE INDUSTRIES

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

• 6.1 TECHNOLOGY ANALYSIS
• 6.2 KEY EMERGING TECHNOLOGIES
  • 6.2.1 AI-DRIVEN FORMULATION & COMPOUNDING MANAGEMENT
  • 6.2.2 AUTOMATED & ROBOTIC COMPOUNDING SYSTEMS
• 6.3 ADJACENT TECHNOLOGIES
  • 6.3.1 BARCODE & IMAGE-BASED VERIFICATION TECHNOLOGIES
  • 6.3.2 CLOSED-SYSTEM TRANSFER & CONTAINMENT TECHNOLOGIES
• 6.4 COMPLEMENTARY TECHNOLOGIES
  • 6.4.1 ELECTRONIC PRESCRIBING & COMPOUNDING WORKFLOW MANAGEMENT
  • 6.4.2 CLOUD-BASED PHARMACY MANAGEMENT & DATA ANALYTICS
• 6.5 TECHNOLOGY/PRODUCT ROADMAP
• 6.6 FUTURE APPLICATIONS
• 6.7 IMPACT OF AI/GEN AI ON COMPOUNDING PHARMACY MARKET
  • 6.7.1 TOP USE CASES & MARKET POTENTIAL
  • 6.7.2 CASE STUDIES OF AI IMPLEMENTATION IN COMPOUNDING PHARMACY MARKET
  • 6.7.3 INTERCONNECTED ADJACENT ECOSYSTEM & IMPACT ON MARKET PLAYERS
  • 6.7.4 CLIENTS' READINESS TO ADOPT GENERATIVE AI IN COMPOUNDING PHARMACY MARKET

7 SUSTAINABILITY & REGULATORY LANDSCAPE

• 7.1 REGIONAL REGULATIONS & COMPLIANCE
  • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS, BY REGION
  • 7.1.2 INDUSTRY STANDARDS
• 7.2 SUSTAINABILITY INITIATIVES
• 7.3 IMPACT & REGULATORY POLICY INITIATIVES
• 7.4 CERTIFICATIONS, LABELING, & ECO-STANDARDS

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

• 8.1 DECISION-MAKING PROCESS
• 8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
  • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 8.2.2 KEY BUYING CRITERIA
• 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
• 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
• 8.5 MARKET PROFITABILITY

9 COMPOUNDING PHARMACY MARKET, BY PRODUCT

• 9.1 INTRODUCTION
• 9.2 ORAL DRUGS
  • 9.2.1 INCREASING DEMAND FOR PRECISE AND CUSTOMIZABLE ORAL FORMULATIONS IN UNMET PATIENT POPULATIONS TO DRIVE MARKET
• 9.3 TOPICAL DRUGS
  • 9.3.1 RISING DEMAND FOR PERSONALIZED TOPICAL TREATMENTS AND ADVANCED DELIVERY VEHICLES TO FUEL MARKET GROWTH
• 9.4 PARENTERAL DRUGS
  • 9.4.1 RISING DEMAND FOR STERILE INJECTABLE THERAPIES AND SUPPLY-CHAIN DISRUPTIONS TO BOOST MARKET GROWTH
• 9.5 OPHTHALMIC DRUGS
  • 9.5.1 RISING CASES OF EYE-RELATED DISORDERS TO ACCELERATE MARKET GROWTH
• 9.6 NASAL DRUGS
  • 9.6.1 ADVANCEMENTS IN NASAL DRUG DELIVERY SYSTEMS AND FAVORABLE REGULATORY POLICIES TO PROPEL MARKET GROWTH
• 9.7 RECTAL DRUGS
  • 9.7.1 PERSONALIZED FORMULATIONS AND REGULATORY SUPPORT TO DRIVE GROWTH IN RECTAL COMPOUNDING THERAPIES
• 9.8 OTHER PRODUCTS

10 COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE

• 10.1 INTRODUCTION
• 10.2 PHARMACEUTICAL DOSAGE ALTERATION
  • 10.2.1 TAILORED DOSAGE FORMS TO ENHANCE PATIENT ADHERENCE AND CUSTOMIZATION IN COMPOUNDED MEDICATIONS
• 10.3 PHARMACEUTICAL INGREDIENT ALTERATION
  • 10.3.1 INCREASED NEED FOR CUSTOMIZED PHARMACEUTICAL INGREDIENTS TO ENHANCE PATIENT-CENTRIC COMPOUNDING SOLUTIONS
• 10.4 CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING
  • 10.4.1 PERSISTENT GLOBAL DRUG SHORTAGES AND LIMITATIONS OF LARGE-SCALE PHARMACEUTICAL PRODUCTION TO PROPEL ADOPTION

11 COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION

• 11.1 INTRODUCTION
• 11.2 PAIN MANAGEMENT
  • 11.2.1 NEED FOR PERSONALIZED PAIN RELIEF SOLUTIONS FOR CHRONIC AILMENTS TO SUPPORT MARKET
• 11.3 HORMONE REPLACEMENT THERAPY
  • 11.3.1 POPULARITY OF PERSONALIZED HORMONE THERAPIES TO DRIVE STEADY GROWTH IN GLOBAL COMPOUNDING PHARMACY MARKET
• 11.4 DERMAL DISORDERS
  • 11.4.1 CUSTOMIZED DERMATOLOGICAL SOLUTIONS TO PROPEL GLOBAL COMPOUNDING PHARMACY MARKET EXPANSION
• 11.5 NUTRITIONAL SUPPLEMENTS
  • 11.5.1 PERSONALIZED NUTRACEUTICALS TO OFFER NICHE BUT BETTER GROWTH OPPORTUNITIES IN COMPOUNDING PHARMACIES
• 11.6 OTHER THERAPEUTIC APPLICATIONS

12 COMPOUNDING PHARMACY MARKET, BY STERILITY

• 12.1 INTRODUCTION
• 12.2 STERILE
  • 12.2.1 RTU/RTA STERILE PREPARATIONS AND OPHTHALMIC PACKS TO DRIVE RAPID GROWTH IN COMPOUNDING PHARMACIES
• 12.3 NON-STERILE
  • 12.3.1 503A/MAGISTRAL NON-STERILE PREPARATIONS TO DRIVE GLOBAL VOLUME AND VALUE LEADERSHIP IN COMPOUNDING PHARMACIES

13 COMPOUNDING PHARMACY MARKET, BY END USER

• 13.1 INTRODUCTION
• 13.2 ADULTS
  • 13.2.1 RISING CHRONIC DISEASE BURDEN AND PERSONALIZED THERAPIES TO AUGMENT ADULT SEGMENT GROWTH
• 13.3 GERIATRIC PATIENTS
  • 13.3.1 AGING DEMOGRAPHICS AND DOSE-FORM CUSTOMIZATION TO PROPEL GERIATRIC SEGMENT GROWTH
• 13.4 PEDIATRIC PATIENTS
  • 13.4.1 CUSTOMIZED DOSAGE FORMS AND PEDIATRIC-SPECIFIC NEEDS TO DRIVE GROWTH

14 COMPOUNDING PHARMACY MARKET, BY REGION

• 14.1 INTRODUCTION
• 14.2 NORTH AMERICA
  • 14.2.1 US
    • 14.2.1.1 US to dominate North American compounding pharmacy market during forecast period
  • 14.2.2 CANADA
    • 14.2.2.1 Personalized treatments, regulatory reinforcement, and supply-gap filling to fuel global compounding pharmacy growth
• 14.3 EUROPE
  • 14.3.1 GERMANY
    • 14.3.1.1 Aging demographics, technological advancements, and supportive regulations to drive market
  • 14.3.2 UK
    • 14.3.2.1 Personalized treatments, chronic disease management, and regulatory support to support market growth
  • 14.3.3 FRANCE
    • 14.3.3.1 Focus on chronic disease management to fuel growth in French compounding pharmacy market
  • 14.3.4 ITALY
    • 14.3.4.1 Rising commercial drug development pipeline to spur market growth
  • 14.3.5 SPAIN
    • 14.3.5.1 Global regulatory advancements and rising R&D activities to drive market
  • 14.3.6 REST OF EUROPE
• 14.4 ASIA PACIFIC
  • 14.4.1 CHINA
    • 14.4.1.1 Low manufacturing cost and high demand for medicines to favor market growth
  • 14.4.2 JAPAN
    • 14.4.2.1 Increasing prevalence of chronic diseases and growing geriatric population to fuel demand for customized medications
  • 14.4.3 INDIA
    • 14.4.3.1 Increasing pharma R&D activities to support market growth
  • 14.4.4 AUSTRALIA
    • 14.4.4.1 Innovation in clinical practice and regulatory support to accelerate compounding pharmacy growth
  • 14.4.5 SOUTH KOREA
    • 14.4.5.1 Regulatory innovation and automation to fuel South Korean compounding pharmacy market growth
  • 14.4.6 REST OF ASIA PACIFIC
• 14.5 LATIN AMERICA
  • 14.5.1 BRAZIL
    • 14.5.1.1 Growing pharmacy & biologics manufacturing sectors and rising R&D spending to drive market
  • 14.5.2 MEXICO
    • 14.5.2.1 Regulatory improvements, high cancer rates, and robust pharmaceutical industry to boost market growth
  • 14.5.3 REST OF LATIN AMERICA
• 14.6 MIDDLE EAST & AFRICA
  • 14.6.1 GCC COUNTRIES
    • 14.6.1.1 Rising demand for biologics and increasing prevalence of non-communicable diseases to propel market growth
  • 14.6.2 REST OF MIDDLE EAST & AFRICA

15 COMPETITIVE LANDSCAPE

• 15.1 INTRODUCTION
• 15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN COMPOUNDING PHARMACY MARKET, 2024-2026
• 15.3 REVENUE ANALYSIS, 2023-2025
• 15.4 MARKET SHARE ANALYSIS, 2025
• 15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
  • 15.5.1 STARS
  • 15.5.2 EMERGING LEADERS
  • 15.5.3 PERVASIVE PLAYERS
  • 15.5.4 PARTICIPANTS
  • 15.5.5 COMPETITIVE BENCHMARKING: KEY PLAYERS, 2025
    • 15.5.5.1 Company footprint
    • 15.5.5.2 Region footprint
    • 15.5.5.3 Product footprint
    • 15.5.5.4 Therapeutic application footprint
    • 15.5.5.5 Sterility footprint
• 15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
  • 15.6.1 PROGRESSIVE COMPANIES
  • 15.6.2 RESPONSIVE COMPANIES
  • 15.6.3 DYNAMIC COMPANIES
  • 15.6.4 STARTING BLOCKS
  • 15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
    • 15.6.5.1 Detailed list of key startup/SMEs
    • 15.6.5.2 Competitive benchmarking of key startups/SMEs
• 15.7 COMPANY VALUATION & FINANCIAL METRICS
  • 15.7.1 FINANCIAL METRICS
  • 15.7.2 COMPANY VALUATION
• 15.8 BRAND/PRODUCT COMPARISON
• 15.9 COMPETITIVE SCENARIO
  • 15.9.1 PRODUCT LAUNCHES
  • 15.9.2 DEALS
  • 15.9.3 EXPANSIONS

16 COMPANY PROFILES

• 16.1 KEY PLAYERS
  • 16.1.1 BAXTER
    • 16.1.1.1 Business overview
    • 16.1.1.2 Products offered
    • 16.1.1.3 Recent developments
      • 16.1.1.3.1 Product launches
      • 16.1.1.3.2 Expansions
    • 16.1.1.4 MnM view
      • 16.1.1.4.1 Key strengths
      • 16.1.1.4.2 Strategic choices
      • 16.1.1.4.3 Weaknesses & competitive threats
  • 16.1.2 EMPOWER PHARMACY
    • 16.1.2.1 Business overview
    • 16.1.2.2 Products offered
    • 16.1.2.3 Recent developments
      • 16.1.2.3.1 Product launches
      • 16.1.2.3.2 Expansions
    • 16.1.2.4 MnM view
      • 16.1.2.4.1 Key strengths
      • 16.1.2.4.2 Strategic choices
      • 16.1.2.4.3 Weaknesses & competitive threats
  • 16.1.3 B. BRAUN SE
    • 16.1.3.1 Business overview
    • 16.1.3.2 Products offered
    • 16.1.3.3 Recent developments
      • 16.1.3.3.1 Product launches
    • 16.1.3.4 MnM view
      • 16.1.3.4.1 Key strengths
      • 16.1.3.4.2 Strategic choices
      • 16.1.3.4.3 Weaknesses & competitive threats
  • 16.1.4 FAGRON
    • 16.1.4.1 Business overview
    • 16.1.4.2 Products offered
    • 16.1.4.3 Recent developments
      • 16.1.4.3.1 Deals
      • 16.1.4.3.2 Expansions
    • 16.1.4.4 MnM view
      • 16.1.4.4.1 Key strengths
      • 16.1.4.4.2 Strategic choices
      • 16.1.4.4.3 Weaknesses & competitive threats
  • 16.1.5 QUVA PHARMA, INC.
    • 16.1.5.1 Business overview
    • 16.1.5.2 Products offered
    • 16.1.5.3 Recent developments
      • 16.1.5.3.1 Expansions
    • 16.1.5.4 MnM view
      • 16.1.5.4.1 Key strengths
      • 16.1.5.4.2 Strategic choices
      • 16.1.5.4.3 Weaknesses & competitive threats
  • 16.1.6 SCA PHARMA
    • 16.1.6.1 Business overview
    • 16.1.6.2 Products offered
    • 16.1.6.3 Recent developments
      • 16.1.6.3.1 Product launches
      • 16.1.6.3.2 Deals
  • 16.1.7 NEPHRON PHARMACEUTICALS
    • 16.1.7.1 Business overview
    • 16.1.7.2 Products offered
    • 16.1.7.3 Recent developments
      • 16.1.7.3.1 Expansions
  • 16.1.8 LEITERS HEALTH
    • 16.1.8.1 Business overview
    • 16.1.8.2 Products offered
    • 16.1.8.3 Recent developments
      • 16.1.8.3.1 Product Launches
      • 16.1.8.3.2 Expansions
  • 16.1.9 ICON GROUP
    • 16.1.9.1 Business overview
    • 16.1.9.2 Products offered
    • 16.1.9.3 Recent developments
      • 16.1.9.3.1 Deals
  • 16.1.10 ROSEWAY LABS
    • 16.1.10.1 Business overview
    • 16.1.10.2 Products offered
    • 16.1.10.3 Recent developments
      • 16.1.10.3.1 Deals
  • 16.1.11 ITH PHARMA
    • 16.1.11.1 Business overview
    • 16.1.11.2 Products offered
    • 16.1.11.3 Recent developments
      • 16.1.11.3.1 Expansions
  • 16.1.12 PENCOL COMPOUNDING PHARMACY
    • 16.1.12.1 Business overview
    • 16.1.12.2 Products offered
  • 16.1.13 FORMUL8
    • 16.1.13.1 Business overview
    • 16.1.13.2 Products offered
  • 16.1.14 AURORA COMPOUNDING PHARMACY
    • 16.1.14.1 Business overview
    • 16.1.14.2 Products offered
• 16.2 OTHER PLAYERS
  • 16.2.1 CUSTOM MED APOTHECARY
  • 16.2.2 INSTITUTIONAL PHARMACY SOLUTIONS
  • 16.2.3 FUSION APOTHECARY
  • 16.2.4 INNOVATION COMPOUNDING PHARMACY
  • 16.2.5 RX3 COMPOUNDING PHARMACY
  • 16.2.6 DOUGHERTY'S PHARMACY, INC.
  • 16.2.7 LORRAINE'S PHARMACY
  • 16.2.8 WELLS PHARMA
  • 16.2.9 OLYMPIA PHARMACY
  • 16.2.10 FRESH THERAPEUTICS
  • 16.2.11 MEDIOS AG

17 RESEARCH METHODOLOGY

• 17.1 RESEARCH DATA
  • 17.1.1 SECONDARY DATA
    • 17.1.1.1 Key sources of secondary data
    • 17.1.1.2 Key objective of secondary research
  • 17.1.2 PRIMARY DATA
    • 17.1.2.1 Breakdown of primaries
    • 17.1.2.2 Key objectives of primary research
• 17.2 MARKET ESTIMATION METHODOLOGY
  • 17.2.1 GLOBAL MARKET ESTIMATION
    • 17.2.1.1 Company revenue analysis (bottom-up approach)
    • 17.2.1.2 Revenue share analysis
    • 17.2.1.3 MnM repository analysis
    • 17.2.1.4 Primary interviews
  • 17.2.2 INSIGHTS OF PRIMARY EXPERTS
  • 17.2.3 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH)
• 17.3 MARKET GROWTH RATE PROJECTIONS
• 17.4 DATA TRIANGULATION
• 17.5 STUDY ASSUMPTIONS
• 17.6 RESEARCH LIMITATIONS
• 17.7 RISK ANALYSIS

18 APPENDIX

• 18.1 DISCUSSION GUIDE
• 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 18.3 CUSTOMIZATION OPTIONS
• 18.4 RELATED REPORTS
• 18.5 AUTHOR DETAILS